Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of trastuzumab deruxtecan versus physician's choice chemotherapy in HER2-low unresectable or metastatic breast cancer
MOH_2019-04-15_004749Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan in breast cancer (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression-free survival. Started Mar 2019; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2019-04-15_004749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-04-15_004749.